Ubs Group Ag Oramed Pharmaceuticals Inc. Transaction History

Ubs Group Ag

  • $528 Billion
  • Q1 2025

A detailed history of Ubs Group Ag transactions in Oramed Pharmaceuticals Inc. stock. As of the latest transaction made, Ubs Group Ag holds 35,583 shares of ORMP stock, worth $76,503. This represents 0.0% of its overall portfolio holdings.

Number of Shares
35,583
Previous 112,981 68.51%
Holding current value
$76,503
Previous $273,000 72.16%
% of portfolio
0.0%
Previous 0.0%

Shares

33 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2025

May 13, 2025
SELL
$2.0 - $2.62 $154,796 - $202,782
-77,398 Reduced 68.51%
35,583 $76,000
Q4 2024

Feb 14, 2025
BUY
$2.17 - $2.52 $184,009 - $213,688
84,797 Added 300.87%
112,981 $273,000
Q3 2024

Nov 14, 2024
BUY
$2.21 - $2.63 $41,753 - $49,688
18,893 Added 203.35%
28,184 $68,000
Q2 2024

Aug 13, 2024
BUY
$2.07 - $2.83 $9,608 - $13,136
4,642 Added 99.85%
9,291 $23,000
Q1 2024

May 13, 2024
SELL
$2.18 - $3.58 $909 - $1,492
-417 Reduced 8.23%
4,649 $13,000
Q4 2023

Feb 09, 2024
SELL
$1.71 - $2.57 $1,949 - $2,929
-1,140 Reduced 18.37%
5,066 $11,000
Q3 2023

Nov 09, 2023
BUY
$2.51 - $3.55 $160 - $227
64 Added 1.04%
6,206 $16,000
Q2 2023

Aug 11, 2023
SELL
$2.12 - $4.47 $197,143 - $415,674
-92,992 Reduced 93.8%
6,142 $21,000
Q1 2023

May 12, 2023
BUY
$1.93 - $13.1 $170,654 - $1.16 Million
88,422 Added 825.45%
99,134 $216,000
Q4 2022

Feb 08, 2023
BUY
$5.88 - $12.03 $13,506 - $27,632
2,297 Added 27.3%
10,712 $128,000
Q3 2022

Nov 10, 2022
BUY
$4.6 - $9.91 $17,774 - $38,292
3,864 Added 84.9%
8,415 $54,000
Q2 2022

Aug 10, 2022
BUY
$3.72 - $9.0 $5,654 - $13,680
1,520 Added 50.15%
4,551 $21,000
Q1 2022

May 16, 2022
SELL
$8.19 - $13.89 $87,182 - $147,859
-10,645 Reduced 77.84%
3,031 $26,000
Q4 2021

Feb 14, 2022
BUY
$12.98 - $29.75 $162,275 - $371,934
12,502 Added 1064.91%
13,676 $195,000
Q3 2021

Nov 15, 2021
SELL
$12.13 - $23.82 $309,399 - $607,576
-25,507 Reduced 95.6%
1,174 $26,000
Q2 2021

Aug 13, 2021
BUY
$8.34 - $14.59 $207,649 - $363,261
24,898 Added 1396.41%
26,681 $357,000
Q1 2021

May 12, 2021
BUY
$4.22 - $11.33 $6,967 - $18,705
1,651 Added 1250.76%
1,783 $18,000
Q4 2020

Feb 11, 2021
SELL
$2.48 - $4.64 $22,882 - $42,813
-9,227 Reduced 98.59%
132 $1,000
Q3 2020

Nov 12, 2020
BUY
$2.58 - $4.16 $13,748 - $22,168
5,329 Added 132.23%
9,359 $24,000
Q2 2020

Jul 31, 2020
SELL
$2.87 - $4.12 $10,311 - $14,803
-3,593 Reduced 47.13%
4,030 $15,000
Q1 2020

May 01, 2020
BUY
$2.6 - $5.5 $19,299 - $40,826
7,423 Added 3711.5%
7,623 $24,000
Q4 2019

Feb 14, 2020
SELL
$2.43 - $5.74 $3,727 - $8,805
-1,534 Reduced 88.47%
200 $1,000
Q3 2019

Nov 14, 2019
SELL
$2.88 - $3.96 $544 - $748
-189 Reduced 9.83%
1,734 $6,000
Q2 2019

Aug 14, 2019
BUY
$2.88 - $4.36 $1,995 - $3,021
693 Added 56.34%
1,923 $7,000
Q1 2019

May 14, 2019
SELL
$2.95 - $3.64 $4,622 - $5,703
-1,567 Reduced 56.02%
1,230 $5,000
Q4 2018

Feb 14, 2019
SELL
$3.0 - $4.94 $1,188 - $1,956
-396 Reduced 12.4%
2,797 $9,000
Q3 2018

Nov 14, 2018
SELL
$4.64 - $7.11 $23,074 - $35,358
-4,973 Reduced 60.9%
3,193 $16,000
Q2 2018

Aug 14, 2018
SELL
$6.29 - $8.22 $4,088 - $5,343
-650 Reduced 7.37%
8,166 $61,000
Q1 2018

May 15, 2018
SELL
$6.51 - $9.14 $56,070 - $78,722
-8,613 Reduced 49.42%
8,816 $57,000
Q4 2017

Feb 14, 2018
BUY
$7.95 - $11.15 $118,812 - $166,636
14,945 Added 601.65%
17,429 $157,000
Q3 2017

Nov 14, 2017
BUY
$7.74 - $10.78 $16,904 - $23,543
2,184 Added 728.0%
2,484 $25,000
Q2 2017

Aug 14, 2017
SELL
N/A
-83 Reduced 21.67%
300 $2,000
Q1 2017

Nov 14, 2017
BUY
N/A
383
383 $3,000

Others Institutions Holding ORMP

# of Institutions
62
Shares Held
8.21M
Call Options Held
11.2K
Put Options Held
200
View Full List

About ORAMED PHARMACEUTICALS INC.

ORMP Quotes by TradingView
  • Ticker ORMP
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 38,827,100
  • Market Cap $83.5M
  • Description
  • Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or pills for delivery of polypeptides. Its proprietary flagship product is the ORMD-0801, an orally ingestible insulin capsule, which completed phase II clinical trials for th...
More about ORMP
Track This Portfolio

Track Ubs Group Ag Portfolio

Follow Ubs Group Ag and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email